Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. ObsEva SA
  6. News
  7. Summary
    OBSV   CH0346177709

OBSEVA SA

(OBSV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Press Release: ObsEva Announces Appointment of Luigi Marro as Chief Transformation Officer

09/30/2021 | 01:00am EST

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange

GENEVA, Switzerland -- September 30, 2021 -- ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today announced the appointment of Luigi Marro, as Chief Transformation Officer (CTO) and member of the company's Executive Committee, effective October 1, 2021. Mr. Marro will lead the Company's strategic Commercial Operational Readiness initiative.

"We are delighted to welcome Luigi to ObsEva's executive team," said Brian O'Callaghan, Chief Executive Officer of ObsEva. "Luigi's comprehensive commercial experience in the reproductive health landscape, deep financial expertise and contributions as a consultant thus far, makes him an ideal fit. We are confident that his impressive track record will be invaluable as we continue to pursue regulatory approvals and advance toward commercialization of linzagolix for the treatment of heavy menstrual bleeding and pain associated with uterine fibroids in pre-menopausal women."

Mr. Marro added, "I am excited to be joining ObsEva at this critical juncture and look forward to working with the outstanding team to drive successful transformation outcomes as we prepare linzagolix for market launch in uterine fibroids, if approved."

Luigi Marro is a pharmaceutical and biotech executive with over 20 years of experience. He has a background in finance, operations and has managed global businesses across multiple therapeutic areas from development stages through commercialization. Most recently, Mr. Marro founded his own consulting company to support biotech and pharmaceutical startups. Before this, Mr. Marro served as Chief Financial Officer at Finox Biotech, which launched the first biosimilar recombinant follicle stimulating hormone (r-FSH) product to market. Previously, Mr. Marro held leadership positions at Voisin Life Sciences Consulting SA as Chief Operating Officer and at Merck Serono as Senior Director Strategy Development and Business Performance. Prior to Serono's acquisition by Merck, Mr. Marro held elevating strategic roles. Mr. Marro holds a university degree in Demographic and Economical Statistic Sciences from La Sapienza in Rome as well as a Master of Business Administration from Luiss Management school in Rome.

About ObsEva

ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on new therapies for the treatment of uterine fibroids, endometriosis, and preterm labor. ObsEva is listed on the Nasdaq Global Select Market and is traded under the ticker symbol "OBSV" and on the SIX Swiss Exchange where it is traded under the ticker symbol "OBSN". For more information, please visit www.ObsEva.com.

Cautionary Note Regarding Forward Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "believe," "expect," "may," "plan," "potential," "will," and similar expressions, and are based on ObsEva's current beliefs and expectations. These forward-looking statements include expectations regarding the clinical development of and commercialization plans for ObsEva's product candidates, including linzagolix, expectations regarding regulatory and development milestones, including the potential timing of regulatory submissions to the EMA and FDA and ObsEva's ability to obtain and maintain regulatory approvals for its product candidates, and the results of interactions with regulatory authorities. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, clinical development and related interactions with regulators, ObsEva's reliance on third parties over which it may not always have full control, the impact of the novel coronavirus outbreak, and other risks and uncertainties that are described in the Risk Factors section of ObsEva's Annual Report on Form 20-F for the year ended December 31, 2020, filed with the Securities and Exchange Commission (SEC) on March 5, 2021 and other filings ObsEva makes with the SEC. These documents are available on the Investors page of ObsEva's website at www.ObsEva.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:

CEO Office contact

Shauna Dillon

Shauna.dillon@obseva.ch https://www.globenewswire.com/Tracker?data=B75_JgdSBwMCAWj7kx3NOktoKvK-2BmLiI4FIj8EycYc1Iao_oiEXXIymZXhTMT0whvpFWoEaygXrax9Jx6qw2-RLkfE56m9RJHAR2VH3T4=

+41 22 552 1550

Investor Contact

Joyce Allaire

jallaire@lifesciadvisors.com https://www.globenewswire.com/Tracker?data=OwxTmvNH9WJ9OocIInuwcwetC7AMG5ppvtg0dGt-yxBN-mZywfq5pBEKuX3ykGMQrR7NZneBchvT8QEPO0AQuaAAx4RVIZem0psIqd6fZEunjqWcEXpuarzdCJ4BM6Ul

+1 (617)-435-6602

Attachment

   -- Press Release in Pdf 
      https://ml-eu.globenewswire.com/Resource/Download/87ff75e1-d9ff-452b-9faf-1d270f965201 
 
 
 

(END) Dow Jones Newswires

September 30, 2021 01:00 ET (05:00 GMT)

All news about OBSEVA SA
12/02ObsEva Announces Symposium and Presentation of Clinical Data on Oral GnRH Antagonist Li..
AQ
12/02ObsEva SA Announces Symposium and Presentation of Clinical Data on Oral GnRH Antagonist..
CI
11/29HC Wainwright Adjusts ObsEva's Price Target to $15 From $17, Keeps Buy Rating
MT
11/22ObsEva Shares Rise As FDA Accepts Linzagolix Application
DJ
11/22OBSEVA : Announces U.S. FDA Acceptance of New Drug Application for Linzagolix - Form 6-K
PU
11/22ObsEva Says FDA Accepts New Drug Application for Linzagolix
MT
11/22Obseva's Uterine Fibroids Drug Accepted For Review by US FDA
MT
11/22Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix
AQ
11/22Obseva SA Announces U.S. FDA Acceptance of New Drug Application for Linzagolix
CI
11/22Obseva Announces Appointment of Stephanie Brown to its Board of Directors
AQ
More news
Analyst Recommendations on OBSEVA SA
More recommendations
Financials (USD)
Sales 2021 20,1 M - -
Net income 2021 -55,1 M - -
Net Debt 2021 - - -
P/E ratio 2021 -3,29x
Yield 2021 -
Capitalization 179 M 179 M -
Capi. / Sales 2021 8,88x
Capi. / Sales 2022 40,1x
Nbr of Employees 43
Free-Float 86,9%
Chart OBSEVA SA
Duration : Period :
ObsEva SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OBSEVA SA
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 2,40 $
Average target price 15,00 $
Spread / Average Target 525%
EPS Revisions
Managers and Directors
Brian O'Callaghan Chief Executive Officer & Director
David Renas Chief Financial Officer
Frank A. G. M. Verwiel Chairman
Jean-Pierre Gotteland Chief Scientific Officer, Head-R&D
Elizabeth Ijeoma Onyemelukwe Garner Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
OBSEVA SA15.38%179
GILEAD SCIENCES, INC.19.65%87 443
BIONTECH SE258.12%70 510
REGENERON PHARMACEUTICALS35.38%68 384
WUXI APPTEC CO., LTD.24.26%64 686
VERTEX PHARMACEUTICALS-12.58%52 531